Amgen is facing false claims suit, firm discloses following SB Clinical Labs settlement.
AMGEN NAMED IN FALSE CLAIMS ACT WHISTLEBLOWER SUIT, the company revealed in a Feb. 26 Securities & Exchange Commission filing. "Amgen has been advised that it and certain purchasers of its products have been named as defendants in a civil lawsuit initiated by a former employee of Amgen," the company said. The suit was brought in Philadelphia federal court but is under seal pending Department of Justice review.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth